PharmaEngine (4162) - Net Assets
Based on the latest financial reports, PharmaEngine (4162) has net assets worth NT$4.79 Billion TWD (≈ $151.06 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$4.91 Billion ≈ $154.62 Million USD) and total liabilities (NT$112.86 Million ≈ $3.56 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 4162 financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$4.79 Billion |
| % of Total Assets | 97.7% |
| Annual Growth Rate | 50.88% |
| 5-Year Change | 34.62% |
| 10-Year Change | 70.92% |
| Growth Volatility | 213.86 |
PharmaEngine - Net Assets Trend (2009–2024)
This chart illustrates how PharmaEngine's net assets have evolved over time, based on quarterly financial data. Also explore total assets of PharmaEngine for the complete picture of this company's asset base.
Annual Net Assets for PharmaEngine (2009–2024)
The table below shows the annual net assets of PharmaEngine from 2009 to 2024. For live valuation and market cap data, see 4162 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$5.40 Billion ≈ $170.12 Million |
+39.79% |
| 2023-12-31 | NT$3.86 Billion ≈ $121.70 Million |
-0.24% |
| 2022-12-31 | NT$3.87 Billion ≈ $121.99 Million |
-1.69% |
| 2021-12-31 | NT$3.94 Billion ≈ $124.09 Million |
-1.81% |
| 2020-12-31 | NT$4.01 Billion ≈ $126.37 Million |
+15.16% |
| 2019-12-31 | NT$3.48 Billion ≈ $109.73 Million |
-5.72% |
| 2018-12-31 | NT$3.69 Billion ≈ $116.38 Million |
-5.55% |
| 2017-12-31 | NT$3.91 Billion ≈ $123.22 Million |
+2.96% |
| 2016-12-31 | NT$3.80 Billion ≈ $119.68 Million |
+20.25% |
| 2015-12-31 | NT$3.16 Billion ≈ $99.53 Million |
+7.95% |
| 2014-12-31 | NT$2.93 Billion ≈ $92.20 Million |
+7.67% |
| 2013-12-31 | NT$2.72 Billion ≈ $85.63 Million |
+66.44% |
| 2012-12-31 | NT$1.63 Billion ≈ $51.45 Million |
+164.05% |
| 2011-12-31 | NT$618.48 Million ≈ $19.49 Million |
+659.60% |
| 2010-12-31 | NT$81.42 Million ≈ $2.57 Million |
+621.06% |
| 2009-12-31 | NT$11.29 Million ≈ $355.76K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to PharmaEngine's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 263526900000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$2.13 Billion | 39.47% |
| Other Components | NT$3.27 Billion | 60.53% |
| Total Equity | NT$5.40 Billion | 100.00% |
PharmaEngine Competitors by Market Cap
The table below lists competitors of PharmaEngine ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Oriental Precision & Engineering Co.Ltd
KQ:014940
|
$245.08 Million |
|
Kernex Microsystems (India) Limited
NSE:KERNEX
|
$245.09 Million |
|
Export Inv
TA:EXPO
|
$245.18 Million |
|
Innoprise Plantations Bhd
KLSE:6262
|
$245.26 Million |
|
Ace Bed Company Limited
KQ:003800
|
$245.03 Million |
|
Launch Two Acquisition Corp. Class A Ordinary Shares
NASDAQ:LPBB
|
$244.72 Million |
|
Falcon Oil & Gas Ltd.
V:FO
|
$244.71 Million |
|
Pennar Industries Limited
NSE:PENIND
|
$244.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PharmaEngine's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,862,913,000 to 5,399,798,000, a change of 1,536,885,000 (39.8%).
- Net income of 1,751,030,000 contributed positively to equity growth.
- Dividend payments of 215,444,000 reduced retained earnings.
- Other comprehensive income decreased equity by 327,834,000.
- Other factors increased equity by 329,133,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$1.75 Billion | +32.43% |
| Dividends Paid | NT$215.44 Million | -3.99% |
| Other Comprehensive Income | NT$-327.83 Million | -6.07% |
| Other Changes | NT$329.13 Million | +6.1% |
| Total Change | NT$- | 39.79% |
Book Value vs Market Value Analysis
This analysis compares PharmaEngine's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.46x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 314.44x to 1.46x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$0.17 | NT$54.90 | x |
| 2010-12-31 | NT$0.94 | NT$54.90 | x |
| 2011-12-31 | NT$5.92 | NT$54.90 | x |
| 2012-12-31 | NT$13.20 | NT$54.90 | x |
| 2013-12-31 | NT$20.11 | NT$54.90 | x |
| 2014-12-31 | NT$19.88 | NT$54.90 | x |
| 2015-12-31 | NT$21.38 | NT$54.90 | x |
| 2016-12-31 | NT$25.82 | NT$54.90 | x |
| 2017-12-31 | NT$26.47 | NT$54.90 | x |
| 2018-12-31 | NT$25.03 | NT$54.90 | x |
| 2019-12-31 | NT$23.90 | NT$54.90 | x |
| 2020-12-31 | NT$27.49 | NT$54.90 | x |
| 2021-12-31 | NT$27.21 | NT$54.90 | x |
| 2022-12-31 | NT$26.95 | NT$54.90 | x |
| 2023-12-31 | NT$26.87 | NT$54.90 | x |
| 2024-12-31 | NT$37.58 | NT$54.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PharmaEngine utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 32.43%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 69.39%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.08x
- Recent ROE (32.43%) is above the historical average (-47.83%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -874.10% | 0.00% | 0.00x | 3.70x | NT$-99.83 Million |
| 2010 | -59.14% | 0.00% | 0.00x | 1.17x | NT$-56.29 Million |
| 2011 | 46.20% | 89.27% | 0.50x | 1.03x | NT$223.86 Million |
| 2012 | 3.00% | 26.62% | 0.11x | 1.01x | NT$-114.32 Million |
| 2013 | -4.34% | -315.10% | 0.01x | 1.01x | NT$-389.66 Million |
| 2014 | 4.22% | 53.97% | 0.08x | 1.01x | NT$-169.06 Million |
| 2015 | 12.47% | 77.68% | 0.16x | 1.03x | NT$78.10 Million |
| 2016 | 18.15% | 60.77% | 0.29x | 1.04x | NT$309.75 Million |
| 2017 | 9.90% | 45.34% | 0.21x | 1.05x | NT$-4.04 Million |
| 2018 | 3.50% | 44.09% | 0.08x | 1.04x | NT$-240.05 Million |
| 2019 | 1.22% | 13.55% | 0.09x | 1.05x | NT$-305.75 Million |
| 2020 | 15.07% | 57.22% | 0.25x | 1.05x | NT$203.17 Million |
| 2021 | 10.82% | 65.06% | 0.16x | 1.02x | NT$32.17 Million |
| 2022 | 8.23% | 48.72% | 0.16x | 1.02x | NT$-68.42 Million |
| 2023 | 7.11% | 35.78% | 0.19x | 1.02x | NT$-111.64 Million |
| 2024 | 32.43% | 69.39% | 0.43x | 1.08x | NT$1.21 Billion |
Industry Comparison
This section compares PharmaEngine's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,782,670,400
- Average return on equity (ROE) among peers: 2.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PharmaEngine (4162) | NT$4.79 Billion | -874.10% | 0.02x | $245.05 Million |
| Apex Biotechnology Corp (1733) | $1.35 Billion | 29.84% | 0.15x | $89.90 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $3.42 Billion | 0.26% | 0.72x | $188.76 Million |
| Panion & BF Biotech Inc (1760) | $2.01 Billion | 9.08% | 0.54x | $184.23 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $3.36 Billion | 1.58% | 0.42x | $68.46 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $996.24 Million | 6.00% | 0.56x | $99.61 Million |
| Level Biotechnology (3118) | $522.28 Million | 13.08% | 0.40x | $34.35 Million |
| GenMont Biotech Inc (3164) | $290.14 Million | -2.84% | 0.08x | $47.96 Million |
| Medigen Biotechnology (3176) | $3.54 Billion | -16.06% | 0.36x | $144.62 Million |
| Sagittarius Life Science (3205) | $965.47 Million | -11.83% | 0.10x | $119.60 Million |
| Genovate Biotechnology Co Ltd (4130) | $1.38 Billion | 0.03% | 0.10x | $98.37 Million |
About PharmaEngine
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematol… Read more